Disease · HP_0001268

Mental deterioration

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Mental deterioration. Diseases, record HP_0001268. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001268

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Mental deterioration
Open Targets ID: HP_0001268
Other names: Cognitive decline, Cognitive decline, progressive, Intellectual deterioration, Progressive cognitive decline
Highest stage of its drugs: Phase 3, for 3 of its 42 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs42

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CHOLECALCIFEROL	CHEMBL1042	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LIRAGLUTIDE	CHEMBL4084119	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OMEGA-3 FATTY ACIDS	CHEMBL4298065		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NAPROXEN	CHEMBL154	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ROFECOXIB	CHEMBL122	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ERGOCALCIFEROL	CHEMBL1536	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ESTRADIOL	CHEMBL135	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CHOLINE ALFOSCERATE	CHEMBL6067974		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOSERINE	CHEMBL771	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 42

See all 42 drugs

Targets98

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ACHE	Acetylcholinesterase	3	Acetylcholinesterase inhibitor	Unknown	https://conductscience.org/library/genes/43	Drugs and targets
INSR	Insulin receptor	2	Insulin receptor agonist	Phase 2	https://conductscience.org/library/genes/3643	Drugs and targets
PTGS2	Cyclooxygenase	2	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Phase 2/3	https://conductscience.org/library/genes/5743	Drugs and targets
VDR	Vitamin D3 receptor	2	Vitamin D receptor agonist	Phase 3	https://conductscience.org/library/genes/7421	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/152	Drugs and targets
AGER	Advanced glycosylation end product-specific receptor	1	Advanced glycosylation end product-specific receptor antagonist	Phase 1/2	https://conductscience.org/library/genes/177	Drugs and targets
APP	Amyloid-beta precursor protein	1	Amyloid-beta A4 protein disrupting agent	Phase 2	https://conductscience.org/library/genes/351	Drugs and targets
CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1B	1	Voltage-gated N-type calcium channel alpha-1B subunit blocker	Phase 2	https://conductscience.org/library/genes/774	Drugs and targets

1 to 10 of 98

See all 98 targets

Trials29

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00114517	ELITE: Early Versus Late Intervention Trial With Estradiol	Phase 2	643	2017-06-08	Atherosclerosis	ESTRADIOL	Its record names the disease	ClinicalTrials.gov
NCT02415556	Memory Aid by Intranasal Insulin in Diabetes (MemAID)	Phase 2	289	2021-09-17	Type 2 Diabetes Mellitus	INSULIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT04292535	Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise	Phase 2	116	2021-06-21	Insulin, Exercise	INSULIN ASPART	Its record names the disease	ClinicalTrials.gov
NCT00736996	Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)	Phase 2	78	2016-01-15	Mild Cognitive Impairment	PIOGLITAZONE	Its record names the disease	ClinicalTrials.gov
NCT01361633	The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly	Phase 2	51	2012-06-21	Treatment, Placebo	CYCLOSERINE	Its record names the disease	ClinicalTrials.gov
NCT02874924	Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly	Phase 2	34	2018-12-04	Aging	SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT04103086	ARomatherapy for Cognitive Trajectory in Chinese After Percutaneous Coronary Intervention (ARCTIC-PCI)	Not applicable	660		Percutaneous Coronary Intervention	(+)-MENTHOL, MENTHOL	Its record names the disease	ClinicalTrials.gov
NCT07589595	A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)	Phase 2	350		Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid	DONANEMAB	Its record names the disease	ClinicalTrials.gov
NCT07244770	The Effects of Some Antihyperglycemic Drugs on Cognitive Function and Risk of Depression of Diabetic Patients		300		MCI	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT00105105	Mifepristone as Adjunctive Therapy in Alzheimer's Disease	Phase 2	160		Alzheimer's Disease	MIFEPRISTONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 29

See all 29 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
17B-estradiol vs Placebo: deaths from any cause	1 of 323	1 of 320	643	NCT00114517	Trial comparisons
17B-estradiol vs Placebo: serious adverse events	43 of 323	45 of 320	643	NCT00114517	Trial comparisons
Medication vs Sugar Pill: serious adverse events	0 of 19	0 of 23	42	NCT01361633	Trial comparisons

Papers from its trials19

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35482079	RESULT	1	PubMed
27421538	RESULT	1	PubMed
27028912	RESULT	1	PubMed
12783912	RESULT	1	PubMed
42211793	DERIVED	1	PubMed
39980346	DERIVED	1	PubMed
36539060	DERIVED	1	PubMed
35526057	DERIVED	1	PubMed
34736575	DERIVED	1	PubMed
34250817	DERIVED	1	PubMed

1 to 10 of 19

See all 19 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0001268

GET https://conductscience.org/api/diseases/v1/HP_0001268/drugs?page=2

API reference For AI assistants